The E2F8 Knockout HeLa Polyclonal Cells provide a pooled, CRISPR/Cas9-edited HeLa cell population with targeted disruption of the E2F8 gene. As polyclonal knockout cells, they represent a heterogeneous mixture of edited alleles, eliminating the need for single-cell cloning while capturing a broad spectrum of genetic alterations. This format offers a cost-effective and biologically relevant loss-of-function model for dissecting E2F8-mediated transcriptional control in a widely used human cell line.
The host cell line, HeLa, is an immortalized human cervical adenocarcinoma line derived from a patient in 1951. It is HPV18-positive, exhibiting characteristic epithelial morphology and aggressive growth properties. HeLa cells have been indispensable in biomedical research for decades, serving as a standard model for studying cell cycle regulation, viral oncogenesis, signal transduction, and drug responses. Their well-annotated genome and ease of culture make them an ideal chassis for gene-editing applications.
E2F8 belongs to the atypical E2F repressor family and functions independently of classical pocket protein partners. It forms heterodimers with TFDP1 or TFDP2 and interacts with RB1 (pRB) and HDAC1 to actively repress target gene transcription. E2F8 itself is a transcriptional target of E2F1, creating a negative feedback loop within the pRB/E2F pathway. Under hypoxic conditions, HIF1?? induces E2F8 expression, linking oxygen sensing to cell cycle control. E2F8 directly binds and represses promoters of CCNE1 (Cyclin E), CDC6, VEGFA, and MYC, thereby inhibiting G1/S transition and angiogenic signaling. Additional crosstalk with Wnt/??-catenin components further positions E2F8 as a nodal regulator of proliferation and differentiation.
In HeLa cells, disruption of E2F8 relieves transcriptional repression of Cyclin E and VEGFA, potentially accelerating cell cycle progression and angiogenic output. This phenotype recapitulates molecular features observed in cancers where E2F8 is frequently downregulated or mutated, such as hepatocellular carcinoma, breast carcinoma, and lung adenocarcinoma. The polyclonal nature of the product means that the population contains a range of knockout alleles, from partial to full disruption, enabling researchers to evaluate dose-dependent effects of E2F8 loss in a cervical cancer-derived epithelial context. This model is especially valuable for dissecting how E2F8 deficiency synergizes with HPV-driven oncogenic programs.
These polyclonal knockout cells are optimised for a variety of applications, including quantitative assessment of cell cycle distribution via propidium iodide staining and flow cytometry, proliferation rate measurement using MTT or BrdU incorporation assays, and transcriptomic profiling by RNA-seq. Classical molecular biology techniques such as Western blotting and RT-qPCR allow direct verification of downstream target derepression (e.g., Cyclin E, VEGFA). The cells can also be used in functional angiogenesis assays, including endothelial tube formation, and serve as a screening platform for compounds that target E2F8-dependent pathways. For further information, please contact Ascent Research.
